Cargando…

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering

Agonistic CD27 monoclonal antibodies (mAb) have demonstrated impressive anti-tumour efficacy in multiple preclinical models but modest clinical responses. This might reflect current reagents delivering suboptimal CD27 agonism. Here, using a novel panel of CD27 mAb including a clinical candidate, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heckel, Franziska, Turaj, Anna H., Fisher, Hayden, Chan, H. T. Claude, Marshall, Michael J. E., Dadas, Osman, Penfold, Christine A., Inzhelevskaya, Tatyana, Mockridge, C. Ian, Alvarado, Diego, Tews, Ivo, Keler, Tibor, Beers, Stephen A., Cragg, Mark S., Lim, Sean H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921514/ https://www.ncbi.nlm.nih.gov/pubmed/35288635 http://dx.doi.org/10.1038/s42003-022-03182-6

Ejemplares similares

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms
por: Simpson, Alexander P., et al.
Publicado: (2022)

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies
por: Yu, Xiaojie, et al.
Publicado: (2018)

Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity
por: Yu, Xiaojie, et al.
Publicado: (2020)

Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc
por: Dadas, Osman, et al.
Publicado: (2023)

Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives
por: Dadas, Osman, et al.
Publicado: (2023)

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity
por: Yu, Xiaojie, et al.
Publicado: (2021)

Rational engineering of Fc/Fc receptor interactions to improve antibody potency
por: Doberstein, S, et al.
Publicado: (2003)

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
por: Liu, Rena, et al.
Publicado: (2020)

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking
por: Turaj, Anna H., et al.
Publicado: (2018)

FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion
por: Oldham, Robert J, et al.
Publicado: (2020)

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment
por: Turaj, Anna H., et al.
Publicado: (2017)

Boosting therapeutic potency of antibodies by taming Fc domain functions
por: Kang, Tae Hyun, et al.
Publicado: (2019)

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors: Fc-mediated avidity enhances the potency of an anti-TLR4 antibody
por: Loyau, Jérémy, et al.
Publicado: (2014)

Immune characterization of pre-clinical murine models of neuroblastoma
por: Webb, Emily R., et al.
Publicado: (2020)

Domain binding and isotype dictate the activity of anti-human OX40 antibodies
por: Griffiths, Jordana, et al.
Publicado: (2020)

Editorial: Roles of Fc Receptors in Disease and Therapy
por: Ganesan, Latha P., et al.
Publicado: (2020)

Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations
por: Torgeman, Amram, et al.
Publicado: (2017)

Height, but not binding epitope, affects the potency of synthetic TCR agonists
por: Wilhelm, Kiera B., et al.
Publicado: (2021)

Height, but not binding epitope, affects the potency of synthetic TCR agonists
por: Wilhelm, Kiera B., et al.
Publicado: (2021)

Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
por: Stopforth, Richard J., et al.
Publicado: (2016)

Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
por: Thomas, Lawrence J, et al.
Publicado: (2014)

Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
por: Shiakolas, Andrea R., et al.
Publicado: (2021)

Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human FcγRI
por: Bonetto, Stephane, et al.
Publicado: (2009)

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
por: Schriek, Angela I., et al.
Publicado: (2022)

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
por: Ramakrishna, Venky, et al.
Publicado: (2015)

Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates
por: Shen, Yijun, et al.
Publicado: (2017)

Genetic dissection of a major haplotype associated with arthritis reveal FcγR2b and FcγR3 to act additively
por: Vaartjes, Daniëlle, et al.
Publicado: (2020)

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions
por: Schriek, Angela I., et al.
Publicado: (2022)

Strong association of mast cells with eosinophilic esophagitis‐specific signatures
por: Alvarado, Diego, et al.
Publicado: (2022)

On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation
por: Sopp, Joshua M., et al.
Publicado: (2021)

Cross-Reactivity, Epitope Mapping, and Potency of Monoclonal Antibodies to Class 5 Fimbrial Tip Adhesins of Enterotoxigenic Escherichia coli
por: Liu, Yang, et al.
Publicado: (2020)

The Value of High Potencies
por: Winans, Theo. H.
Publicado: (1895)

Induction and Suppression of an Autoimmune Disease by Oligomerized T Cell Epitopes: Enhanced in Vivo Potency of Encephalitogenic Peptides
por: Falk, Kirsten, et al.
Publicado: (2000)

Fcγ Receptor-Mediated Inflammation Inhibits Axon Regeneration
por: Zhang, Gang, et al.
Publicado: (2014)

Linker Length Matters, Fynomer-Fc Fusion with an Optimized Linker Displaying Picomolar IL-17A Inhibition Potency
por: Silacci, Michela, et al.
Publicado: (2014)

Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions
por: Ding, Huandi, et al.
Publicado: (2023)

Specific peptide conjugation to a therapeutic antibody leads to enhanced therapeutic potency and thermal stability by reduced Fc dynamics
por: Kiyoshi, Masato, et al.
Publicado: (2023)

Summary of carcinogenic potency and positivity for 492 rodent carcinogens in the carcinogenic potency database.
por: Gold, L S, et al.
Publicado: (1989)

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
por: White, Ann L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p63to6togmqe5l9b3ef11ouvkr